

network, and further studies are planned to monitor these important molecules in psychiatric patients.

The Authors would like to thank Mrs. Gianna Pascuttini, for technical assistance. Grant support: CNR 92.0245. CT 04 to G.A. Botta.

### PROBLEMS IN RECOGNIZING PSYCHIATRIC DIFFICULTIES IN A FRENCH OVERSEAS DEPARTMENT: GUADELOUPE

D. Maurer, M. Amar. *Child and Adolescent Department, Centre Hospitalier du Rouvray, B.P. 45 76301 Sotteville Les Rouen Cedex*

Based on an experience in Guadeloupe, and on research for a doctoral thesis, the authors will present problems related to recognizing psychiatric difficulties which practitioners have encountered in a West Indian world, constructed under two influences: one being metropolitan and Cartesian, and the other being African predominated by magic.

By applying semiological knowledge derived from the French nosography, certain pathologies are easily recognized with the same frequency as found on the mainland, whereas others seem to have different forms and modes of expression, such as masked-over depressions or delusional crises. We shall therefore distinguish between the pathologies which seem to be found in common in France, and by extension in Europe, and those which seem to be indigenous to West India where magic-religious thought is dominated by projective-persecutory mechanisms.

This will enable us to evaluate the place to be given to European psychiatry, and its future in a French department which belongs to the European Community.

### INFLUENCE OF MEALS ON THE BIOAVAILABILITY AND SIDE EFFECTS OF CARBAMAZEPINE

H.J. Assion, U. Werner, M. Theisohn. *Institute of Pharmacology, Gleuelerstrasse 24, Cologne, Germany*

The study was conducted to investigate the influence of meals on the bioavailability and the side effects of carbamazepine (CBZ).

**Method:** A sample of 9 probands (5 female, 4 male, age: 23–35 years) were taking a standard or retard tablet (600 mg) in a randomized cross-over design either 5 hours before or after a standardized breakfast. Serum and urine were collected over 1 week and the concentration of CBZ and the metabolites were determined with HPLC. Pharmacokinetic parameters (AUC, C<sub>max</sub>, T<sub>max</sub>) were calculated.

**Results:** The results show a significant lower maximum of the CBZ serum levels of the retard versus the standard formulation. After intake of meals the retard is significantly higher versus "no breakfast". Bioavailability and recovery are comparable for standard-, retard formulation and the modes of administration.

**Conclusion:** The results show a significant influence of meals on the pharmacokinetic parameters of CBZ and should be considered when applying this medication.

[1] Neuvonen PJ: Bioavailability and central side effects of different carbamazepine tablets. *Int Clin Pharmacol* 23, 1985: 226–232

### THERAPY-RESPONSE AND COMORBIDITY IN PATIENTS WITH THERAPY-RESISTANT DEPRESSION

U. Bailer, G. Lenz, A. Neumeister. *Allgemeines Krankenhaus, Department of Psychiatry, University of Vienna, Währinger Gürtel 18–20, A-1090 Vienna, Austria*

30 patients with therapy-resistant depression who had attended the Vienna outpatient-clinic for therapy-resistant depression in the period of April 1993 to August 1994 for the first time, were followed

up 3 months later and efficacy of therapy strategies were evaluated with HAMD and CGI.

At 3-months-follow-up 6 patients (20%) showed a full response (HAMD after 3 months < 6), 8 patients (26.7%) showed a partial response and 13 patients (43.3%) did not respond at all.

(3 patients (10%) were not followed-up and could therefore not be classified).

Independent of their assignment to one of the responder groups, TRD patients presented with following diagnosis of comorbidity:

As comorbidity on axis I (DSM-III-R) anxiety disorder was especially predominant (38.4%), followed by drug abuse by 23.1% of the patients.

Among personality disorders a predominance of dependent personality could be seen (42.8%), followed by avoidant personality by 28.6% of the patients.

A separate analysis of comorbidity characteristics of the two responder groups (non-responders and partial-/full-responders) did not show any statistically significant differences. This was done with reference to comorbidity on axis I and II.

### INTRODUCING A COMPUTER DRIVEN CARE PROGRAMME APPROACH

R.J. Bale, T.P. Burns, M.T. Fiander. *St George's Hospital Medical School, Section of Community Psychiatry, Department of General Psychiatry, Jenner Wing, Cranmer Terrace, London SW17 0RE, United Kingdom*

The drive to introduce systematised care programming has fostered increased computerisation and the development of specific software packages. These packages need to be practical, user friendly and to provide benefit to the professionals using them in terms of methods of working and data collection.

**Method:** A computerised care programme package was implemented as part of a randomised controlled trial evaluating intensive case management for the severely mentally ill. The software was tailored locally so that the categories of care reflected the task oriented activities of the mental health workers/case managers. The software forces users to write a structured care programme, to review their care plans and to confirm when tasks are completed. The prospective collection of activity data on computer enables rapid analysis of activity patterns. The reliability of this data was tested by comparison with case notes.

**Results:** Data obtained from the software has been successfully used to provide activity reports for managers (e.g. frequency, duration and nature of client contacts). Staff report that recording activity data in this way provides a helpful structure to guide their care programming, enables staff to evaluate their care patterns and promotes a greater clarity of thinking.

**Conclusion:** Despite a number of practical problems, a computer driven care programme approach is a usable clinical tool that also provides hard measures of mental health professionals' activity. It also enables model guidance and programme replication.

### PATIENTS' VIEWS ABOUT THEIR PSYCHIATRIC CARE: A ONE YEAR FOLLOW UP STUDY

D. Barker, M. Orrell. *Department of Psychiatry, University College London Medical School, Wolfson Building, Riding House Street, London W1N 8AA, UK*

Poor satisfaction and negative attitudes to psychiatric services and psychiatrists may unduly affect compliance, promptness in seeking help and the patient's understanding and retention of information. In an earlier questionnaire study of 137 acute psychiatric in-patients (Barker et al 1996, in press) we found that 61.2% were satisfied with

their care but 52.7% felt there were many things about their treatment that could be improved. The aim of this study was to follow up these patients one year later and investigate how patients attitudes and levels of satisfaction with psychiatric care change over time.

The initial questionnaire looking at patient satisfaction was modified and aimed at all the responders of the first study. Questionnaires were sent by post. Non-responders were followed up by personal visit. Details on the use of psychiatric services and any changes in social circumstances was also obtained.

There were 87 (80.6%) responders out of the 108 traceable subjects. 50 (57.5%) of responders had been readmitted at some stage during the one year interim. At follow up 72.1% were satisfied with the care they had received and 43.3% felt there were many things about their treatment that could have been improved. A substantial proportion of those (40.9%) who had felt they did not require psychiatric care acknowledged this need on retrospect.

Most aspects of satisfaction appear to be relatively stable over time. Many patients felt dissatisfied with their previous care despite no longer being in hospital. This study helps us to understand the relationship between satisfaction and outcome of psychiatric care.

#### SEROTONIN SELECTIVE REUPTAKE INHIBITORS (SSRI) AND REVERSIBLE SELECTIVE MAO-A (RIMA) COMBINATION TREATMENT IN REFRACTORY DEPRESSION

N. Bazin, P. Fremont. *CHG Lagny-Marne la Vallée, 77500 Lagny sur Marne, France*

Combination treatment is often effective in resistant depressive disorders and several combined treatment have been used successfully. The old irreversible non selective monoamine oxidase inhibitors (MAOIs) have well established efficacy in depression but their co-administration with other anti depressive drugs is dangerous. Several cases of severe adverse events were attributed to "serotonin syndrome". This restriction is not relevant for new reversible and selective MAO-A.

Co-administration of Serotonin Selective Reuptake Inhibitors (SSRI), and Reversible and selective MAO-A Inhibitors (RIMA) is rare. Few authors studied the tolerability in healthy volunteers and reported that this association did not precipitate symptoms of the "serotonin syndrome". This combination treatment has been recently proposed to patients with resistant depressive disorder. These studies report good efficiency and good tolerability.

At Lagny sur Marne hospital, near Paris, twelve patients with refractory depression were treated with the association of one Serotonin Selective Reuptake Inhibitors (SSRI) including paroxetine, fluvoxamine and fluoxetine, and moclobemide, a Reversible and selective MAO-A Inhibitors (RIMA). This association was well tolerated with very few side effects, and demonstrated good efficacy in already all cases. We propose to present our experience of this new combined treatment of resistant depressive disorders.

#### USE OF MAINTENANCE ECT BY NORTH WEST PSYCHIATRISTS

M. Susan, Benbow Tench, David Tench. *Central Manchester NHS Trust, Scope, Carisbrooke Resource Centre, Wenlock Way, Manchester, M12 5LF, UK*

123 psychiatrists completed postal questionnaires regarding their use of ECT — 25% of them stated that they use maintenance ECT (MECT) and a further 42% had not used MECT but would be prepared to consider it. A second stage questionnaire was sent to those who had either used or were prepared to consider using MECT. The main indications for maintenance treatment were the failure of

prophylactic mood drugs or rapid relapse after repeated courses of ECT. 95% of respondents stated that they would use Lithium before considering MECT and 79% would use Carbamazepine. The most common diagnosis amongst patients treated with Maintenance ECT was recurrent depressive illness.

*Pippard & Ellam's* survey of ECT in Great Britain in 1980 found that 22% of psychiatrists used MECT, most rarely. This survey suggests that since then there has been little change and psychiatrists continue to find a group of patients, mainly with unipolar depressive illnesses, for whom MECT is deemed useful.

#### ELECTROCONVULSIVE THERAPY (ECT) AS STRESS, INCREASES NERVE GROWTH FACTOR (NGF) PLASMA LEVELS IN PSYCHIATRIC PATIENTS

G. Bersani<sup>1</sup>, L. Aloe<sup>2</sup>, A. Iannitelli<sup>1</sup>, P. Maselli<sup>1</sup>, E. Alleva<sup>3</sup>, F. Angelucci<sup>2</sup>, P. Orsi<sup>4</sup>, P. Pancheri<sup>1</sup>. <sup>1</sup> *III Psychiatric Clinic, University "La Sapienza"*, <sup>2</sup> *Institute of Neurobiology, CNR*, <sup>3</sup> *Lab of Organ and System Pathophysiology, ISS*, <sup>4</sup> *Institute of Anaesthesia, University "La Sapienza", Rome, Italy*

There are many evidences about the important role played by NGF in stressful events in animal and in the response to psychic stress in the human species. Aim of the study was to verify if ECT, looked as a particular stress, modifies NGF plasma levels in psychiatric patients.

We studied a sample of 14 male inpatients (age = 17–44; mean = 28.28) meeting DSM III-R criteria for different psychiatric disorders (paranoid schizophrenia, N = 4; disorganized schizophrenia, N = 3; undifferentiated schizophrenia, N = 2; schizophreniform disorder, N = 1; obsessive-compulsive disorder, N = 3; major depression, N = 1) compared with 12 male patients (age = 18–59; mean = 38.17; paranoid schizophrenia, N = 2; undifferentiated schizophrenia, N = 1; disorganized schizophrenia, N = 1; catatonic schizophrenia, N = 2; major depression, N = 6) submitted to first ECT session. In the first sample two blood sampling, 10 min apart, each ten milliliter, were collected from the peripheral vein of arm connected to a saline infusion and the times were called -10 and 0 min (baseline). In the patients submitted to ECT, blood sampling was performed each time at -5 min, 0 min (baseline) after the anaesthesia and then after the starting of convulsion. NGF levels were measured in plasma. The technique used was ELISA (the method sensitivity was < 1 pg/ml).

In the two samples a statistical analysis using t-test for paired data was conducted to evaluate eventual significative differences in mean NGF plasma levels at times -10 min and 0 min (baseline). In the first sample as no significative difference was recorded (mean variation = 0.027; t = 0.31; p = 0.75) any stress relate to blood sampling was ruled out. On the contrary, in the patients treated with ECT an important difference was recorded (mean variation = 33.42; t = 1.90; p = 0.086). In the patients submitted to first ECT mean NGF values at -5 min were higher to those seen in the first sample of patients whose blood was sampled at standard conditions (untreated patients, mean = 14.83 pg/ml; ECT treated patients mean = 76.98 pg/ml).

This finding could be viewed as a response to the psychological stress induced by expectation of ECT. In fact a dramatic event such as ECT may be considered as a stressful procedure. Mean NGF values decrease at time 0 min (baseline), perhaps due to adaptation and coping with stress. These last results we obtained for the 4th and the 8th ECT session too.